Lilly’s acquisition of Merida Biosciences is being positioned as a strategic extension into Fc-based therapies that can directly address pathogenic autoantibodies, with the deal framed as valued up to $2.88 billion. The coverage emphasizes Merida’s Fc therapeutic MER511, which targets anti-TSHR autoantibodies for Graves’ disease and thyroid eye disease, and details Merida’s funding history and lead program. The announcement also highlights the cross-border deal pattern around Lilly’s continued acquisition cadence in 2026 and reinforces that this is a platform-like expansion rather than a one-off drug purchase. Key focus areas remain early clinical translation, given the asset’s initial Phase I work and the planned further development steps. Investors will look for how Lilly structures milestones and whether it plans a faster clinical path for the Graves/TED indication portfolio compared with other immunology buys of the year.